A study of HRS-1893 for obstructive hypertrophic cardiomyopathy
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests an investigational drug called HRS-1893 in people with obstructive hypertrophic cardiomyopathy, a condition where the heart muscle is thickened and blocks blood flow. The study aims to see if the drug can improve symptoms and heart function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a BMI under 35.
- You have been diagnosed with obstructive hypertrophic cardiomyopathy.
- Your resting left ventricular outflow tract gradient is at least 50 mmHg, or at least 30 mmHg at rest and rises to 50 mmHg with Valsalva maneuver.
- Your left ventricular ejection fraction is 60% or higher.
- You have New York Heart Association class II or III symptoms (mild to moderate shortness of breath or fatigue with activity).
- You are willing to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world information about people with obstructive hypertrophic cardiomyopathy (HCM) who are being treated with mavacamten or other standard medicines. It aims to understand patient characteristics, treatment choices over time, and long-term outcomes.
This study tests the long-term safety of the drug HRS-1893 in people with hypertrophic cardiomyopathy who have already been in a previous HRS-1893 study. It helps doctors learn more about how safe the drug is over time.
This trial tests a medication called Ademetionine for people with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thick and blocks blood flow). It aims to see if the drug can help improve symptoms and exercise ability.
This trial tests a new treatment that uses radiofrequency energy (similar to heat) to shrink the thickened heart muscle blocking blood flow. It is for people with obstructive hypertrophic cardiomyopathy who have symptoms despite medication and are not able or willing to have heart surgery.
This study tests a new medicine, BHB-1893, against a common heart medicine called metoprolol for people with a heart condition that makes it harder for the heart to pump blood. The goal is to see if BHB-1893 improves symptoms like chest pain and shortness of breath better than the standard medicine.
This trial tests a new drug, Aom0304, for people with hypertrophic cardiomyopathy (a condition where the heart muscle is thickened) who still have symptoms despite standard treatments. The study aims to see if the drug can improve symptoms and heart function.
Hear when a new Obstructive Hypertrophic Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.